Carta al EditorRabdomiólisis yatrógena en un paciente con cardiopatía isquémicaIatrogenic rhabdomyolysis in a patient with ischemic heart disease
Bibliografía (10)
- et al.
Interacciones medicamentosas de agentes hipolipemiantes: Aproximación para establecer y valorar su relevancia clínica. Revisión estructurada
Farm Hosp.
(2013) - et al.
Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatina
J Am Pharm Assoc (2003).
(2015) - et al.
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Eur Heart J.
(2015) - et al.
Diferencias en los resultados de la atención a los pacientes con síndrome coronario agudo con elevación del segmento ST (SCACEST) en función del acceso inicial a hospitales con o sin sala de hemodinámica en Andalucía
Emergencias.
(2014) - Simons M, Cutlip D, Lincoff AM. Antiplatelet agents in acute non-ST elevation acute coronary syndromes. UpToDate....
There are more references available in the full text version of this article.
Cited by (3)
Development of an LC-MS/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin
2019, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesCitation Excerpt :However, co-administration of TIC with other drugs might lead to life-threatening interactions. Recently, several cases have been reported of interaction between TIC and atorvastatin (AT), resulting in rhabdomyolysis [7–9]. Of note, the patients were elderly (>62 years of age) and the dose of AT was at least 40 mg per day.
© 2015 Elsevier España, S.L.U. All rights reserved.